Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 25, Issue 5, 2008, Pages 445-450

  Choi, Seong Hye ^a   Kim, Sang Yun ^c,h   Na, Hae Ri ^b   Kim, Byung Kun ^d   Yang, Dong Won ^e   Kwon, Jay C ^f   Park, Mee Young ^g  

^a Inha University School of Medicine   (South Korea)

^b Bobath Memorial Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Eulji University School of Medicine   (South Korea)

^e The Catholic University of Korea College of Medicine   (South Korea)

^f Changwon Fatima Hospital   (South Korea)

^g Yeungnam University College of Medicine   (South Korea)

^h Seoul National University Bundang Hospital   (South Korea)

Author keywords

Alzheimer's disease; Apolipoprotein E; Donepezil

Indexed keywords

APOLIPOPROTEIN E; DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; TREATMENT RESPONSE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; TREATMENT OUTCOME;

EID: 43049150437     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000124752     Document Type: Article

References (30)

1. McGowan SH, Wilcock GK, Scott M: Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry 1998;13:625-630.
2. Saumier D, Murtha S, Bergman H, Phillips N, Whitehead V, Chertkow H: Cognitive predictors of donepezil therapy response in Alzheimer disease. Dement Geriatr Cogn Disord 2007;24:28-35.
3. Cacabelos R, Llovo R, Fraile C, Fernández-Novoa L: Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res 2007;4:479-500.
4. Varsaldi F, Miglio G, Scordo MG, Dahl ML, Villa LM, Biolcati A, Lombardi G: Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol 2006;62:721-726.
5. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH, Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998;338:506-511.
6. Masullo C, Daniele A, Seripa D, Filippini V, Gravina C, Carbone G, Gainotti G, Fazio VM: Apolipoprotein E genotype in sporadic early- and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:121-125.
7. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL: Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 1998;50:669-677.
8. Wallin AK, Gustafson L, Sjögren M, Wattmo C, Minthon L: Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement Geriatr Cogn Disord 2004;18:197-206.
9. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W: APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:69-77.
10. Almkvist O, Jelic V, Amberla K, Hellström-Lindahl E, Meurling L, Nordberg A: Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 2001;12:22-32.
11. Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C, Masullo C: Apolipoprotein E ε4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:254-261.
12. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT; Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
13. Burns A, Gauthier S, Perdomo C: Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:806-812.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical Diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
15. Folstein MF, Folstein SE, McHugh PR: Minimental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
16. Kang Y, Na DL, Hahn S: A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc 1997;15:300-307.
17. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
18. Dubois B, Slachevsky A, Litvan I, Pillon B: The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621-1626.
19. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
20. Kang SJ, Choi SH, Lee BH, Jeong Y, Hahm DS, Han IW, Cummings JL, Na DL: Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). J Geriatr Psychiatry Neurol 2004;17:32-35.
21. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
22. Choi SH, Na DL, Lee BH, Hahm D, Jeong JH, Yoon SJ, Yoo KH, Ha CK, Han IW, Dementia Research Group: Estimating the validity of the Korean version of Expanded Clinical Dementia Rating (CDR) scale. J Korean Neurol Assoc 2001;19:585-591.
23. Kang SJ, Choi SH, Lee BH, Kwon JC, Na DL, Han SH, Dementia Research Group: The reliability and validity of the Korean Instrumental Activities of Daily Living (K-IADL). J Korean Neurol Assoc 2002;20:8-14.
24. Farlow M, Lane R, Kudaravalli S, He Y: Differential qualitative responses to rivastigmine in APOE ε 4 carriers and noncarriers. Pharmacogenomics J 2004;4:332-335.
25. Petersen RC, Thomas RC, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study Group: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388.
26. Bartolini M, Bertucci C, Cavrini V, Andrisano V: β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003;65:407-416.
27. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-307.
28. Mori F, Lai CC, Fusi F, Giacobini E: Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995;6:633-636.
29. Weisgraber KH: Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994;45:249-302.
30. Ye S, Huang Y, Müllendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW: Apolipoprotein (Apo) E4 enhances amyloid β peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci USA 2005;102:18700-18705.